It summarises key information, practice guidelines and additional resources in a very practical manner. The Influenza Diabetes Community (IDC) has contributed to the chapter on people living with diabetes.

On 4 January, the Member States of the EU, in the presence of the Schengen Associated Countries, met in the framework of the Integrated Political Crisis Response (IPCR) to discuss the epidemiological situation in the EU/EEA and developments in China.

ECDC, together with the EU/EEA Member States and the European Commission has increased its monitoring activities and will revise risk assessments and adjust actions if needed.

Immunity from monovalent COVID-19 mRNA vaccination wanes over time. A bivalent COVID-19 mRNA booster dose is recommended for all eligible persons; however, little is known about its effectiveness against COVID-19 hospitalization.

The information on the coronavirus outbreak is continually evolving. The content within this activity serves as a historical reference to the information that was available at the time of this publication.

2022 has been a big year for diabetes research, filled with historic moments and world-firsts. Here we take a look back at some of the incredible progress Diabetes UK-funded scientists and diabetes researchers across the globe have been behind this year. 

This article assess the effect of RSV fusion protein (F) conformation on B cell responses in a post hoc comparison of samples from the DS-Cav1 [prefusion (pre-F)] and MEDI7510 [postfusion (post-F)] vaccine clinical trials.

Living with diabetes can be hard. The Influenza Hub seeks to educate and raise awareness about influenza and the best way to prevent getting infected by the flu virus.

It has been hypothesized that SARS-CoV-2 infection in children can increase risk of developing type 1 diabetes.

RSV infection in children is the most common viral respiratory infection and can cause severe lung damage or death. There is no licensed vaccine for preventing RSV infection.

Watch Robert Yates, political health economist specialising in Universal Health Coverage (UHC) at Chatham House, discuss with The Economist on the International UHC Day.

This project was commissioned to collect evidence focused on specific life-course approach to immunization (LCI) policies and priority geographies, and to compare available data sets and case studies before and during the COVID-19 pandemic.